Clinical Trial Update: Neoadjuvant Sintilimab Plus Chemoradiotherapy for Locally Advanced Adenocarcinoma of Esophagogastric Junction [Phase 2]

View source ↗

Summary

Phase 2 neoadjuvant trial evaluating sintilimab in combination with chemoradiotherapy for locally advanced adenocarcinoma of the gastroesophageal junction.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adenocarcinoma of the Gastroesophageal Junction

Drugs mentioned

• Sintilimab (sintilimab)

Snippet

Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Conditions: PD-1, Neoadjuvant Chemoradiotherapy | Phase 2 | Status: UNKNOWN